Spyre Therapeutics, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On February 9, 2022, Sara Brownstein advised the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) that she would resign as a Class I director of the Board, effective on February 9, 2022. The Company believes Ms. Brownstein’s resignation was due to disagreement regarding the Company’s financing plans.
Extracted from this filing and checked against the source text.
Sara Brownstein resigned as Class I Director at Spyre Therapeutics, Inc..
On February 9, 2022, Sara Brownstein advised the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) that she would resign as a Class I director of the Board, effective on February 9, 2022. The Company believes Ms. Brownstein’s resignation was due to disagreement regarding the Company’s financing plans.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.